These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Efficacy and safety of biological DMARDs modulating B cells in primary Sjögren's syndrome: Systematic review and meta-analysis. Letaief H, Lukas C, Barnetche T, Gaujoux-Viala C, Combe B, Morel J. Joint Bone Spine; 2018 Jan; 85(1):15-22. PubMed ID: 28673789 [Abstract] [Full Text] [Related]
26. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, Roudaut A, Jamin C, Renaudineau Y, Roué IQ, Cochener B, Youinou P, Saraux A. Arthritis Rheum; 2007 Mar 15; 57(2):310-7. PubMed ID: 17330280 [Abstract] [Full Text] [Related]
27. The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials. Felten R, Scher F, Sibilia J, Gottenberg JE, Arnaud L. Autoimmun Rev; 2019 Jun 15; 18(6):576-582. PubMed ID: 30959220 [Abstract] [Full Text] [Related]
28. Emerging biological therapies in primary Sjogren's syndrome. Ramos-Casals M, Brito-Zerón P. Rheumatology (Oxford); 2007 Sep 15; 46(9):1389-96. PubMed ID: 17586555 [Abstract] [Full Text] [Related]
31. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X. Ann Rheum Dis; 2007 Mar 15; 66(3):351-7. PubMed ID: 16950808 [Abstract] [Full Text] [Related]
32. [First experience with the application of rituximab for the treatment of patients with Sjogren's syndrome and disease]. Vasil'ev VI, Logvinenko OA, Kokosadze NV, Gaĭduk IV, Varlamova EIu, Kovrigina AM, Gorodetskiĭ VR, Nasonov EL. Vestn Ross Akad Med Nauk; 2009 Mar 15; (2):3-10. PubMed ID: 19283903 [Abstract] [Full Text] [Related]
34. Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study. Alunno A, Carubbi F, Bistoni O, Caterbi S, Bartoloni E, Di Benedetto P, Cipriani P, Giacomelli R, Gerli R. Clin Exp Immunol; 2016 Jun 15; 184(3):284-92. PubMed ID: 26814615 [Abstract] [Full Text] [Related]